BioMedNewsBreaks

ThursdayMar 25, 2021 1:29 pm

BioMedNewsBreaks – Kaival Brands Innovations Group Inc. (KAVL), Bidi Welcome Category Reform in China

Kaival Brands Innovations Group (KAVL), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, has noted recent news from China outlining increased supervision over the e-cigarette category. KAVL, which is the exclusive global distributor of all products manufactured by Bidi Vapor LLC, welcomes the news, particularly as it pertains the BIDI(R) Stick disposable electronic nicotine delivery system (“ENDS”). The company noted that the expanding government regulations align with Kaival Brands' dedicated and thorough efforts to maintain standards of compliance and quality. Kaival Brands and Bidi Vapor observed that the additional supervision of e-cigarette manufacturing should…

Continue Reading

ThursdayMar 25, 2021 1:13 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Achieves Strong Growth Amid Booming Market

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of heart health, brain health and supplementary technologies, reported a revenue increase of 71% from $748,377 in 2019 to $1,276,559 over the 12 months ending December 31, 2020. The company attributes this growth to the transition to its new business selling health nutrition products, which positions HYEX for opportunity in the booming plant-based foods and products industry projected to reach $74.2 billion in 2027. “We changed our name from Grey Cloak Tech Inc. to Healthy Extracts Inc. to more accurately reflect our business,” a recent article quotes Kevin Duke Pitts, director,…

Continue Reading

WednesdayMar 24, 2021 2:16 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Working to Expand Test Portfolio

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which recently received European approval for its COVID-19 rapid and portable test system, has set out to increase its portfolio of tests for different diseases to help fight the current and potential pandemics. XPhyto has partnered with Germany’s 3a-diagnostics GmbH for this, according to an article on the company’s recent announcements. “The company is also working with 3a to develop a portfolio of oral biosensor screening tests that detect bacterial and viral infectious diseases ranging from influenza A to group A strep, as well as focusing on other potential pandemic biosensor tech…

Continue Reading

WednesdayMar 24, 2021 12:55 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Spring 2021 Oncology Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will present at the Spring 2021 Oncology Investor Conference taking place virtually March 29 - April 2, 2021. According to the update, Genprex’s president and CEO, Rodney Varner, will deliver a virtual company overview that includes GNPX’s novel gene therapies for non-small cell lung cancer and diabetes. Varner’s presentation is scheduled to begin at 2 p.m. Eastern Time on Monday, March 29, and he will be available for one-on-one meetings with investors throughout the conference. Genprex invites…

Continue Reading

WednesdayMar 24, 2021 12:44 pm

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Releases Stockholder Letter

180 Life Sciences Corp. (NASDAQ: ATNF) CEO James Woody, MD, PhD, has issued a letter to ATNF stockholders. In the letter he provides an overview of the company’s activities and accomplishments since his last stockholder letter, which was released in November 2020. The letter noted the company’s achievement in both legacy-related issues and strengthening its balance sheet. A highlight mentioned in the letter was that the company had reduced its debt from $5 million to $316,000. Woody also reported that the company had converted $3 million in preferred equity to equity. In the letter, Woody also noted that the company…

Continue Reading

TuesdayMar 23, 2021 11:19 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Biotech Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced that it will participate at the Benzinga Biotech Small Cap Conference taking place from March 24-25, 2021. Vivos Chief Executive Officer, Kirk Huntsman, Chief Financial Officer, Brad Amman, and Investor Relations Officer, Ed Loew, will be presenting at the event with their presentation scheduled to begin at 11:40 a.m. EST on Thursday, March 25, 2021. Investors interested in joining the Vivos presentation can register for a free spectator pass at https://ibn.fm/jQW0J.…

Continue Reading

TuesdayMar 23, 2021 10:59 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Appoints Board Chair as New CEO

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announce the appointment of a new CEO: J. Melville (“Mel”) Engle. Engle is currently serving as chairman of the board and will continue to serve in that role as well as in his new position as CEO. Engle has more than two decades of impressive experience in the biotech and health-care industries. In his various roles as president, CEO, director, chairman of the board, CFO, senior vice president and more, he has gained invaluable expertise and insight into driving sales, unveiling…

Continue Reading

MondayMar 22, 2021 1:53 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Conference Call to Discuss Q4 Numbers, Clinical Pipeline Update

Processa Pharmaceuticals Inc. (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has scheduled a conference call to discuss its fourth-quarter financial report as well as to provide a drug-development update. The conference call and life webcast will be available to any participants dialing or logging in. Interested parties can dial 877-545-0320 in the United States or 973-528-0016 for international calls; the entry code is the same for both: 805295. A replay of the call will be available as well. To access that, interested parties can…

Continue Reading

MondayMar 22, 2021 1:22 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Presents Data Regarding Drug Candidate for Replacement of Addictive Benzodiazepines

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, presented data highlighting the proposed mechanism of action (“MOA”) of its Phase 3 investigational drug candidate, PH94B nasal spray, in a poster session at the Anxiety and Depression Association of America’s 2021 Virtual Annual Conference. VTGN’s PH94B spray is designed to provide rapid-onset acute treatment of anxiety without directly activating gamma-amino butyric acid (“GABA-A”) receptors. This approach differentiates PH94B from benzodiazepines such as alprazolam, diazepam and lorazepam, which are…

Continue Reading

MondayMar 22, 2021 10:06 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Phase 2 MS1819-PERT Combination Clinical Trial

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced completion of enrollment in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (“PERT”). The combination trial is for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). “We are very pleased to have completed enrollment in our Phase 2 MS1819 plus PERT combination therapy clinical trial,” said James Sapirstein, president, CEO and chairman of AzurRx. “Based on the very encouraging clinical results…

Continue Reading